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Abstract
Objective: A right and left hepatic trisectionectomy and an extended trisectionectomy are the largest
liver resections performed for malignancy. This report analyses a series of 23 patients who had at least
one repeat resection after a hepatic trisectionectomy for colorectal liver metastasis (CRLM).
Methods: A retrospective analysis of a single-centre prospective liver resection database fromMay 1996
to April 2009 was used for patient identification. Full notes, radiology and patient reviews were analysed
for a variety of factors with respect to survival.
Results: Twenty-three patients underwent up to 3 repeat hepatic resections after 20 right and 3 left
hepatic trisectionectomies. In 18 patients the initial surgery was an extended trisectionectomy. Overall 1-,
3- and 5-year survival rates after a repeat resection were 100%, 46% and 32%, respectively. No factors
predictive for survival were identified.
Conclusion: A repeat resection after a hepatic trisectionectomy for CRLM can offer extended survival
and should be considered where appropriate.
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Introduction
A hepatic trisectionectomy entails a large liver resection involving
removal of up to 80% of the liver parenchyma.1–6 These proce-
dures are used in highly specialized units primarily for the treat-
ment of extensive and advanced hepatic or biliary disease. A
hepatic trisectionectomy remains the most challenging of the
major anatomic hepatectomies with higher complication rates
than other hepatic resections.4,5 There have been few published
series with these procedures and long-term follow-up has rarely
been considered.4,5,7–12 Recently reported experience with a right
and left hepatic trisectionectomy, and described extensions of
these operations, regarded as extended trisectionectomy, have
been analysed in an attempt to define the current role for these
challenging operations.4,5,9
For hepatic colorectal metastases (CRLM), a liver resection has
greatly improved survival rates, with 5-year survival reported to
be 30% to 60%.13–16 However, after the initial liver resection, recur-
rence occurs in up to 75% of patients and in 20–40% of these
patients, the liver is the only site of recurrence.16–20 At present there
are no clear practice guidelines for the management of recurrent
hepatic metastasis. A repeat liver resection is increasing in popu-
larity, but there are few long-term studies assessing the outcome.
Further, most of the available data relates to patients who have
undergone only a minor liver resection initially.13,15,18,19,21–23
After an extensive hepatic resection, recurrence is more likely
owing to the aggressive nature of the initial disease.24 As there is a
significantly reduced liver volume after the initial resection,
although liver regeneration occurs, important anatomy is altered.
Thus, a repeat liver resection after a hepatic trisectionectomy is
more challenging. This study reports a cohort of patients who
underwent a trisectionectomy or an extended trisectionectomy
and had a repeat hepatectomy with the aim of describing the
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clinical course and surgical techniques used in selected patients in
order to illustrate the difficulties with this patient population.
Patients and methods
A retrospective analysis of a prospective database was undertaken.
The study period was from May 1996 and April 2009. During this
period, a total of 427 patients underwent right and left hepatic
trisectionectomies for a variety of aetiologies. Twenty-three
(5.3%) patients with CRLM subsequently underwent a further
liver resection and were included in this study. The technique for
a trisectionectomy and an extended trisectionectomy has previ-
ously been described.4,5,9 Portal vein embolization was not rou-
tinely used. Future liver remnant function was assessed as
previously described.25 After recurrence of a tumour, patients were
assessed prior to resection with a computed Tomography (CT) of
the thorax, abdomen and pelvis to exclude extrahepatic disease.
More recently, positron emission tomogrophy (PET) CT has been
used to assess any suspicious extrahepatic lesions that were not
fully characterized by CT alone. Patients were only subjected to
re-resection if extrahepatic disease was felt to be resectable (most
often lung metastases). All patients underwent magnetic reso-
nance imaging (MRI) of the liver to delineate the anatomy clearly
and to characterize the tumour. It has been the unit policy never to
biopsy malignant liver lesions when considering surgery because
of the fear of tumour seeding. All resections were performed using
a Cavi-Pulse Ultrasonic Surgical Aspirator (CUSA, Model 200T;
Valley Lab., Boulder, CO, USA), with a Pringle manoeuvre (portal
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Figure 1 A 53-year-old male who had resection of a T1 N0 sigmoid colon cancer in 1993 presented with deranged liver function tests (LFTs).
A cross-section and a coronal oblique magnetic resonance scan (MRI) scan (Fig. 1a) in July 2000 demonstrated a large liver metastasis
obliterating the right lobe and invading the left lobe. The tumour surrounded much of the inferior vena cava (IVC), with obliteration of the right
and middle hepatic veins and it was in close apposition to the left portal triad structures. A surgical resection was by a right hepatic
trisectionectomy, caudate lobectomy (peeling the tumour off the IVC and left hepatic vein), with bile duct excision and a hepaticojejunos-
tomy. Histopathology of the 2.0-kg resection specimen showed a 14-cm-diameter tumour comprised of moderately differentiated adeno-
carcinoma consistent with colorectal origin, with a clear resection margin of 0.5 mm. The patient made an uncomplicated recovery, with
discharge on day 8. He received adjuvant chemotherapy with 5-Fluorouracil (5-FU) for 6 months. In June 2001, a routine follow-up computed
tomography (CT) scan detected further liver metastases and MRI showed three tumours in the liver remnant (Fig. 1b). It was possible to
remove these tumours by metastasectomy – anterior segment 2, anterior segment 3, posterior segment 3. Histopathology demonstrated the
tumours to be 3.3, 2.7 and 2.0 cm in diameter and composed of moderately differentiated adenocarcinoma, with vascular invasion into portal
vein branches. A tumour was seen microscopically at the resection margins in two of the three specimens (R1). No further chemotherapy
was offered by his local oncology team. Follow-up was routine until May 2006 when a CT scan showed an 8-mm pulmonary metastasis,
which was resected with a clear margin, confirmed to be metastatic adenocarcinoma. No chemotherapy was offered at this stage. Further
follow to January 2013 up has been uneventful
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Figure 2 A 50-year-old male presented with synchronous colon cancer and liver metastases in August 2000 and he underwent a left
hemicolectomy in, followed by chemotherapy with 5-Fluorouracil (5-FU). In March 2001, he was assessed for hepatic surgery and imaging
confirmed tumours in every liver segment (Fig. 2a). There was a large right-sided tumour enveloping the inferior vena cava (IVC) and
obliterating the right and middle hepatic veins and the hepatocaval confluence of the left hepatic vein. The portal triad structures to the left
side appeared clear. In June 2001, he underwent a right hepatic trisectionectomy with a caudate lobectomy and resection of parts of
segments 2 and 3 (an extended right trisectionectomy) using total vascular exclusion with in situ hypothermic perfusion and veno-veno
bypass for a 90-min period. Intra-operative ultrasound confirmed tumours in segments 1, 4, 5, 6, 7, 8 and further metastases in segments
2 and 3. The LHV was involved and was partially resected and subsequently reconstructed using a flap created from IVC. The right
hemi-diaphragm was involved and was resected en bloc with the liver and then reconstructed. Histology confirmed adenocarcinoma of a
colorectal origin and showed clear margins from the trisectionectomy, but R1 from the segment 2/3 metastasis. A computed tomography
(CT) scan 6 months post liver surgery revealed a 6-mm deposit in segment 2, which was confirmed on magnetic resonance imaging (MRI)
(Fig. 2b) and he subsequently underwent a repeat metastasectomy in January 2002. Histology confirmed clear margins (R0). He remained
disease free until March 2004 when he required 2 right lung metastasectomies. He then remained well until October 2005, where he was
found to have a large lesion in the left upper lobe, abutting the subclavian artery and another lesion in the same lobe. Both were resected
successfully. In February 2006, follow-up imaging revealed a new liver lesion in the anterior aspect of the remnant. He was recommended
to undergo further chemotherapy, but after 3 cycles of oxaliplatin and 5-FU, treatment ceased owing to significant side effects. MRI and PET
CT in May 2006 revealed 2 small liver metastases in the remnant but there was also marked uptake in the left upper thorax near the trachea
and oesophagus. He underwent further thoracic surgery in August 2006, with resection of a 3.0 ¥ 2.5 cm nodal mass of adenocarcinoma
next to subclavian artery. A further MRI of the liver to re-asses the liver metastasis and this confirmed two new tumours, with an overall size
of 5.3 cm (Fig. 2c). He had a repeat hepatic resection and histology confirmed adenocarcinoma, R1 owing to proximity to important vascular
structures at time of hepatectomy. Owing to the aggressive nature of the disease, the patient was offered further chemotherapy, but declined
due to poor experiences previously. Interim CT scans again remained normal. However, at a clinical review in October 2009, now 8.5 years
after a trisectionectomy, he was noted to have a mass in the anterior abdominal wall with ascites. An MRI scan revealed a 3.7-cm liver
metastasis in the anterior part of the liver remnant and it also demonstrated left hepatic vein stenosis (Fig. 2d). He went on to have left hepatic
vein endovascular stenting and the ascites improved. PET CT and MRI scan in February 2010 confirmed the lesions in the remnant liver with
no extrahepatic disease. He went on to have his third repeat hepatectomy in March 2010, this time R0. This patient remains well at present
with no evidence of recurrent disease on CT in November 2012
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Figure 3 Flow chart detailing colorectal liver metastasis patients (n = 23). Survival times are from first repeat resection after a trisectionec-
tomy or an extended trisectionectomy. *disease free at last assessment
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triad clamping) applied only in selected patients to minimize
blood loss and total vascular exclusion (portal triad and hepatic
vein or inferior vena cava clamping) was used when necessary for
tumours at the hepatocaval confluence. Figures 1 and 2 represent
two of the 23 patients, and demonstrate the complexities of the
types of cases described.
During the 14-year study period, emerging evidence relating to
the use of neoadjuvant and adjuvant chemotherapy has meant
that the policies for the use of these treatments have evolved. In
recent years, 5-flurouracil (5-FU) has been used in combination
with Oxaliplatin or Irinotecan after a liver recection, where in the
past patients only received 5-FU. However, since the beginning of
the study period adjuvant chemotherapy was offered to all liver
resection patients who had not received chemotherapy within the
previous 2 years. It has been this unit’s preference not to use
neo-adjuvant chemotherapy prior to a redo liver resection
because of worries about future liver remnant function. Several
patients in this series received chemotherapy adjuvant to the
primary liver surgery; this is detailed in the results. No patients
were treated with intra-arterial chemotherapy, transarterial chem-
oembolization (TACE) or radiolabelled microspheres.
Follow-up included a general review at 6 weeks post procedure,
followed by CT of the thorax, abdomen and pelvis at 3, 6, 12, 18,
24 months post last resection and blood studies including liver
function tests (LFTs) and tumour markers (CEA, CA19-9). Blood
tests and clinical examinations were then repeated yearly to
10 years, with CT scanning yearly to 5 years and again at 7 and
10 years.
Statistical analysis
Statistical analysis focused on a variety of factors including: sur-
vival time, chemotherapy, the size of tumours, resection margin
status and CEA. Statistical analysis involved Kaplein–Mier sur-
vival plots, the log-rank test and the Mann U-Whitney tests, per-
formed using SPSS 16.0 (SPSS Inc., Chicago, IL, USA).
Results
Demographic data
Twenty-three patients underwent a hepatic trisectionectomy or an
extended trisectionectomy for CRLM: 20 right and 3 left. There
were 16 males and 7 females with an age range of 39 to 77 years at
initial surgery.
Technical aspects
In addition to the hepatic trisectionectomy, a caudate lobectomy
was necessary in six patients (five right and one left). Eighteen
patients had an extended trisectionectomy, with a non-anatomical
resection for tumours in the remaining segments en bloc or sepa-
rately. Of the 20 right trisectionectomies, 15 were extended and all
of the 3 left trisesectionectomies involved resection into segment 6
and/or 7. Total vascular exclusion was applied in five patients, with
four patients requiring hepatic vein reconstruction. All 23 patients
had at least one repeat resection, with 4 patients undergoing
further liver resections at a later date (Fig. 3). Nine patients had
lung resections, with two patients undergoing a second lung resec-
tion and one a third thoracic resection.
Survival
After a hepatic trisectionectomy, the overall 1-, 3-, and 5-year
survival was 100%, 87% and 55%, respectively, after a trisec-
tionectomy, with a median survival of 69 months. After the first
repeat resection 1-, 3, and 5-year survival was 100%, 46% and
32% with a median survival of 32.5 months (Fig. 4). Four
patients had a second repeat resection with a median survival
time of 85.6 months after the first repeat resection, 3 of whom
remain alive. Three patients went on to have a third redo hepa-
tectomy with a median survival of 64.1 months (from first
repeat hepatectomy), with two of these patients remaining alive
and disease free. The median follow-up for the survivors was
87.1 months (n = 7).
The time to redo surgery in the CRLM group was a range of 3.3
to 66.9 months, with a median interval of 14.5 months. All
patients received chemotherapy, eleven patients prior to trisec-
tionectomy and 15 patients had it after a trisectionectomy (all the
patients who did not have it previously and three patients who had
it prior to trisectionectomy). Patients who had chemotherapy
prior to the trisectionectomy had a median time to redo surgery of
8.2 months to redo compared with 25.5 months for patients that
only received it after the trisectionectomy. There was no statistical
difference in survival between the two groups.
After a repeat resection, the median survival in the R0 group
was 45.8 months and in the R1 group was 26.7 months (P =
0.465). Tumours were analysed by size based on previous studies
Number at risk:         14          8              7            7          23
Figure 4 Survival data (overall survival from a repeat resection for
the CRLM group (n = 23). 1-, 3- and 5-year survival was 100%, 46%
and 32%. The median survival was 32.5 months (2.7 years)
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of a repeat hepatectomy for CRLM demonstrating prognostic
significance for tumours <3 cm or <5 cm.19,21 Tumour size did not
significantly influence survival. Plasma CEA levels did not corre-
late with survival.
Complications
Recognizing that the re-resection cohort described in this paper is
selected from patients who survived a trisectionectomy, these
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Evidence of recurrent
hepatic disease on CT
Chemotherapy offered (if not 
previously administered) 
MRI Liver ± PET CT 
Regular follow up (3, 6, 12, 18, 
24 months post procedure, then 
annually) 
CT Thorax Abdomen and Pelvis 
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LFT, CEA, CA19-9 
Patient Review 







Figure 5 Flow chart detailing the management algorithm for this complex group of patients
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patients were fortunate in experiencing few complications. In the
short term, after the initial right or left hepatic trisectionectomy or
extended trisectionectomy, there was one bile leak (managed non-
operatively) and one patient required a laparotomy for bleeding.
One patient developed hepatorenal syndrome after the trisec-
tionectomy, but recovered. There were no significant long-term
complications, although two patients developed incisional
hernias. After a repeat resection, there were no significant short-
term or long-term complications except for patient 10 who
required endovascular stenting for left hepatic vein stenosis.
Discussion
In recent years, a repeat liver resection has been increasing in
popularity as the morbidity and mortality rates from a hepatec-
tomy are low.26 However, a repeat liver resection is technically
demanding because of peri-hepatic adhesions, altered anatomy in
the remnant liver owing to regeneration and often fragile liver
parenchyma because of chemotherapy.13,19 There are several
series reporting a repeat liver resection with good survival
rates.14,18,19,21,22,27 Some of these repeat resections are major, but the
majority remain minor resections (single metastasectomies). A
repeat liver resection is the most challenging after an initial major
liver resection. There has been no series published to date describ-
ing a repeat resection after a hepatic trisectionectomy or extended
trisectionectomy, operations that involve removing up to 80% of
the liver parenchyma. With any repeat resection, the aim is to
improve survival, and this series demonstrates that a continual
aggressive approach achieves this.
It is suggested that in untreated CRLM patients, a median sur-
vival is 4.5 to 6.5 months or up to 24 months for patients treated
with systemic chemotherapy alone.21 In a previous study, this
unit looked at 54 repeat resections for patients with CRLM and
demonstrated a median survival of 50.3 months after a repeat
resection. The 3- and 5-year survival rates after a resection were
53% and 46%, respectively.19 Other previous studies have been
based on repeat resections after smaller primary resections than
in our series but have reported similar results, with 5 year sur-
vivals of 31–38%.13,18,21,22 The data from the current series shows
that the median survival after a hepatic trisectionectomy in
patients who have gone on to develop resectable recurrent
disease was 69 months and a repeat hepatectomy gained a
median extension of 32.5 months, suggesting that operating for
recurrence after a trisectionectomy improves survival. After a
second repeat resection, patients survived for a median of 85.6
months and all the patients who underwent three or more repeat
resections remain alive.
In this series, the median time to a repeat resection was 14.5
months (range, 3.3 to 66.9) and this is similar to studies reported
by De Jong et al. (19.1 months) and Imamura et al. (11
months).13,26 The prognosis of patients who underwent a repeat
hepatic resection at 1 year or less after the initial hepatectomy was
no worse than the prognosis of patients who underwent a repeat
resection with an interval of 1 year or more (P = 0.747). This is
contrary to other previous studies that suggested a repeat hepate-
ctomy in less than 1 year leads to a poorer prognosis.18,26
There is a general consensus that a positive or involved (R1)
resection is associated with early disease recurrence and shorter
long-term survival.18,28 Owing to the scale of resection required for
patients in this series a high R1 resection rate is expected. At repeat
resection, patients who underwent a R0 compared with a R1
resection had slightly higher survival rates, but not significantly. It
has previously been demonstrated that with larger numbers of
patients these differences become significant.19 Owing to the small
number of patients in this cohort, the value of chemotherapy
could not be established.
De Jong et al. found the only significant associated factor for
survival from the time of the second resection was the presence of
extra-hepatic disease (P < 0.001).13 Patients with extra-hepatic
disease at the time of second resection had a median survival of 27
vs. 50 months for those who had intrahepatic disease only (P <
0.001).13 In the current series, nine patients underwent lung resec-
tions for metastases from colorectal cancer. Two of these patients
had a second lung resection.
In summary, this series demonstrates that that a repeat liver
resection after a right and left hepatic trisectionectomy and an
extended trisectionectomy can lead to improved survival for
patients with CRLM. Further, this series illustrates the surgical
challenges in dealing with this complex patient group. Figure 5 is
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